Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hinokitiol is a naturally occurring **tropolone derivative** and monoterpenoid, most commonly isolated from the heartwood of several Cupressaceae (cypress family) trees[3][4]. It has **broad-spectrum antibacterial, antifungal, antioxidant, anti-inflammatory, anti-melanogenic**, and mild **antiviral properties**[3][4][5]. Mechanistically, hinokitiol acts primarily by chelating metal ions (notably iron and copper), which can disrupt metal-dependent bacterial enzymatic systems and generate reactive oxygen species[5][6][11]. It also inhibits NF-κB signaling, suppresses matrix metalloproteinases, and activates caspase-3, contributing to its anti-inflammatory and cytoprotective actions[4]. Hinokitiol is effective against both Gram-positive and Gram-negative bacteria (including methicillin-resistant *Staphylococcus aureus* and some antibiotic-resistant strains), reduces inflammation in dermatologic conditions, and inhibits efflux pumps in bacteria, thereby enhancing the efficacy of tetracycline and bismuth-based antibiotics[5][11]. It is used in some oral care and topical consumer hygiene products, and is investigated primarily as a **dietary supplement or cosmeceutical ingredient**, not as an approved pharmaceutical[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hinokitiol.